Business Context and Reporting Period
This Form 6-K filing by Quoin Pharmaceuticals, Ltd. covers the month of July 2022, with a report date of July 15, 2022. The company is a foreign private issuer based in Tel Aviv, Israel, focused on pharmaceutical development.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on material corporate agreements and structural changes rather than financial performance data.
Material Changes and Corporate Actions
- Altium Growth Fund Agreement: On July 14, 2022, the Company entered an agreement with Altium Growth Fund, LP to amend Series A and Exchange Warrants, reducing the exercise price to $0.00 per ADS. Additionally, the Series C Warrant and a portion of the Series A Warrant were cancelled, and related Securities Purchase Agreements were terminated.
- ADS Ratio Change: On July 12, 2022, the Board approved a change in the ADS ratio from 1 ADS representing 400 Ordinary Shares to 1 ADS representing 5,000 Ordinary Shares. This constitutes a 1-for-12.5 split of outstanding ADSs, effective August 1, 2022.
- Canada Commercialization Agreements: On July 14, 2022, the Company signed a License and Distribution Agreement and a Supply Agreement with Endo Ventures Limited. Endo received exclusive rights to commercialize the product QRX003 in Canada upon regulatory approval, with Quoin responsible for manufacturing and supply.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary regarding future earnings. The primary operational risk and contingency noted is the requirement for applicable regulatory approvals before Endo Ventures can commercialize QRX003 in Canada. The ADS split is subject to compliance with applicable approvals or notification requirements.
Investor Verification Checklist
- Verify the effective date and market impact of the 1-for-12.5 ADS split scheduled for August 1, 2022.
- Review the full text of the Altium Agreement (Exhibit 10.1) to understand the implications of the $0.00 exercise price and warrant cancellations on capital structure.
- Confirm the regulatory status of QRX003 in Canada to assess the timeline for potential revenue generation under the Endo agreement.
- Check subsequent filings for any updates on the ADS ratio change implementation.